TITLE

Infliximab for the treatment of pyrodema gangrenosum: a randomised, double blind, placebo controlled trial

AUTHOR(S)
Brooklyn, T. N.; Dunnill, M. G. S.; Shetty, A.; Bowden, J. J.; Williams, J. D. L.; Griffiths, C. E. M.; Forbes, A.; Greenwood, R.; Probert, C. S.
PUB. DATE
April 2006
SOURCE
Gut;Apr2006, Vol. 55 Issue 4, p505
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Pyoderma gangrenosum (PG) is a chronic ulcerating skin condition that often occurs in association with inflammatory bowel disease. There have been a number of reports of PG responding to infliximab, a monoclonal antibody against tumour necrosis factor α. Aim: In the first randomised placebo controlled trial of any drug for the treatment of PG, we have studied the role of infliximab in this disorder. Subjects: Patients 18 years of age or older with a clinical diagnosis of PG were invited to take part. Methods: Patients were randomised to receive an infusion of infliximab at 5 mg/kg or placebo at week 0. Patients were then assessed at week 2 and non-responders were offered open labelled infliximab. The primary end point was clinical improvement at week 2, with secondary end points being remission and improvement at week 6. Results: Thirty patients were entered into the study. After randomisation, 13 patients received infliximab and 17 patients received placebo. At week 2, significantly more patients in the infliximab group had improved (46% (6/13)) compared with the placebo group (6%(1/17); p = 0.025). Overall, 29 patients received infliximab with 69% (20/29) demonstrating a beneficial clinical response. Remission rate at week 6 was 21% (6/29). There was no response in 31% (9/29) of patients. Conclusions: This study has demonstrated that infliximab at a dose of 5 mg/kg is superior to placebo in the treatment of PG. Open label treatment with infliximab also produced promising results. Infliximab treatment should be considered in patients with PG.
ACCESSION #
20509024

 

Related Articles

  • Use of Infliximab in Particular Clinical Settings: Management Based on Current Evidence. Papa, Alfredo; Mocci, Giammarco; Bonizzi, Michele; Felice, Carla; Andrisani, Gianluca; De Vitis, Italo; Guidi, Luisa; Gasbarrini, Antonio // American Journal of Gastroenterology;Jun2009, Vol. 104 Issue 6, p1575 

    With the increasingly widespread use of the anti-tumor necrosis factor-α agent infliximab for the treatment of Crohn's disease and ulcerative colitis, there have been some concerns raised about the potential consequences of such therapy in particular clinical settings. In this review, we...

  • Use of infliximab in a patient with pyoderma gangrenosum and rheumatoid arthritis. Tada, Masahiro; Nakanishi, Takeshi; Hirata, Chika; Okano, Tadashi; Sugioka, Yuko; Wakitani, Shigeyuki; Nakamura, Hiroaki; Koike, Tatsuya // Modern Rheumatology (Springer Science & Business Media B.V.);Dec2010, Vol. 20 Issue 6, p598 

    Pyoderma gangrenosum (PG) is characterized by ulcerative skin lesions. Infliximab (IFX) may promote PG healing in patients with inflammatory bowel disease, but whether IFX is effective for treating PG in patients with rheumatoid arthritis (RA) has not reported. We report the case of a...

  • Biologics in the management of ulcerative colitis – comparative safety and efficacy of TNF-α antagonists. Fausel, Rebecca; Afzali, Anita // Therapeutics & Clinical Risk Management;2015, Vol. 11, p63 

    Ulcerative colitis can cause debilitating symptoms and complications such as colonic strictures, colonic dysplasia, colorectal cancer, and toxic megacolon or perforation. Goals of treatment in ulcerative colitis include resolution of gastrointestinal symptoms, healing of colonic mucosa, and...

  • Management of Inflammatory Bowel Disease with Infliximab and Other Anti-Tumor Necrosis Factor Alpha Therapies.  // BioDrugs;2010 Supplement 1, Vol. 24, p3 

    No abstract available.

  • Anti-Tumour Necrosis Factor Therapy for Ulcerative Colitis: Evidence to Date. Thukral, Chandrashekhar; Cheifetz, Adam; Peppercorn, Mark A. // Drugs;2006, Vol. 66 Issue 16, p2059 

    Infliximab, the chimeric monoclonal antibody directed against tumour necrosis factor (TNF)-α, has profoundly changed therapy for Crohn's disease (CD). However, for ulcerative colitis (UC), before the publication of ACT 1 and ACT 2 (Active Ulcerative Colitis Trials 1 and 2), there were only a...

  • Use of anti-tumour necrosis factor agents in inflammatory bowel disease: European guidelines for 2001–2003. Schreiber, S.; Campieri, M.; Colombel, J. F.; Van Deventer, S. J. H.; Feagan, B.; Fedorak, R.; Forbes, A.; Gassull, M.; Gendre, J. P.; Van Hogezand, R. A.; Lofberg, R.; Modigliani, R.; Pallone, F.; Petritsch, W.; Prantera, C.; Rampton, D.; Seibold, F.; Vatn, M.; Zeitz, M.; Rutgeerts, P. // International Journal of Colorectal Disease;Jan2001, Vol. 16 Issue 1, p1 

    The introduction of novel anti-tumor necrosis factor (TNF) agents has not only led to impressive new therapeutic opportunities but also resulted in uncertainty regarding their optimal use and possible side effects. Guidelines are presented here for the use of anti-TNF agents in gastrointestinal...

  • CORRECTION.  // Gut;Nov2004, Vol. 53 Issue 11, p1722 

    Several corrections to the articles including "Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor antibody treatment," by S. J. Connor, "Morphological characterisation of Crohn's disease fistulae," by F. Bataille, and "Divergent patterns...

  • Downregulation of CPI-17 contributes to dysfunctional motility in chronic intestinal inflammation model mice and ulcerative colitis patients. Ohama, Takashi; Hori, Masatoshi; Fujisawa, Masahiko; Kiyosue, Masaharu; Hashimoto, Masaki; Ikenoue, Yuka; Jinno, Yoshio; Miwa, Hiroto; Matsumoto, Takayuki; Murata, Takahisa; Ozaki, Hiroshi // Journal of Gastroenterology;2008, Vol. 43 Issue 11, p858 

    Chronic intestinal inflammation is frequently accompanied by motility disorders. We previously reported that proinflammatory cytokines, such as tumor necrosis factor α and interleukin (IL)-1β downregulate CPI-17, an endogenous inhibitor of serine/threonine protein phosphatase in...

  • Efficacy of TNF Antagonists Beyond One Year in Adult and Pediatric Inflammatory Bowel Diseases: A Systematic Review. Oussalah, Abderrahim; Danese, Silvio; Peyrin-Biroulet, Laurent // Current Drug Targets;Feb2010, Vol. 11 Issue 2, p156 

    The introduction in the mid-1990s of tumor necrosis factor (TNF) antagonists changed the treatment of inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis (UC), refractory to conventional medications (corticosteroids, immunomodulators). This review summarizes current data on...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics